Yue Chai
State Key Laboratory Of Emerging Infectious Diseases, Hong Kong Special Administrative Region
Lika, China
Lika, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1.
Journal: Nature communications
Published: April 10, 2025
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.
Journal: Research square
Published: November 28, 2024
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.
Journal: Nature communications
Published: November 14, 2024
Type-II IFN inhibits SARS-CoV-2 replication in human lung epithelial cells and ex vivo human lung tissues through indoleamine 2,3-dioxygenase-mediated pathways.
Journal: Journal of medical virology
Published: August 08, 2023
Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract.
Journal: EBioMedicine
Published: July 31, 2023
Altered host protease determinants for SARS-CoV-2 Omicron.
Journal: Science advances
Published: January 20, 2023
Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2.
Journal: Emerging microbes & infections
Published: August 30, 2022
Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2.
Journal: Cell reports. Medicine
Published: March 29, 2022
Targeting ACLY efficiently inhibits SARS-CoV-2 replication.
Journal: International journal of biological sciences
Published: March 08, 2022
Last Updated: 09/26/2026